LabGenius founder and CEO, Dr James Field
The London-based synthetic biology start-up has secured £2.7m in funding from an oversubscribed seed fund round.
The round was jointly led by Kindred Capital and Acequia Capital with participation from Backed VC, Beast Ventures, Berggruen Holdings Ltd, and System.One.
The round also included former head of corporate strategy at Microsoft, Charlie Songhurst and prominent angel investor, Tom McInerney.
LabGenius, a pioneer in the use of synthetic biology for the development of new materials, will use the funds to establish a purpose-built R&D facility in Central London and mature EVA – its autonomous AI-driven evolution engine.
“EVA is a Silicon Scientist hooked up to a bank of liquid handling robots. By combining intelligence with empirical exploration, EVA is able to iteratively learn through conducting its own scientific experiments,” said LabGenius founder and CEO, Dr James Field.
“Right now, EVA is unpicking Nature’s design rules with unparalleled speed and dexterity. Once equipped with this knowledge, EVA will give us the ability to engineer life with unprecedented control. Critically, this technology will give us the ability to harness new materials and therapies that we do not or even cannot fully understand.”
Leila Zegna, a founding partner at Kindred Capital, added: “We’re delighted to have backed LabGenius. The company is breaking new ground at the interface of synthetic biology and data science and the potential of their technology is vast.”
Our BQ Bulletin emails will land in your inbox at 7.30am, Monday to Friday, with a mix of the latest local business news, national news, and features to inspire you. Sign up here!
Click here to read our privacy statement